Zymeworks BC Inc. Form 8-K: Current report
Filings on SEC EDGAR, newest first; amendments sit with their base form. Values are as filed.
- 2021-12-09: Form 8-K; Period of report 2021-12-09; Description 7.01 Regulation FD Disclosure; Details 7.01.
- 2021-12-09: Form 8-K; Period of report 2021-12-08; Description 7.01 Regulation FD Disclosure; Details 7.01.
- 2021-12-01: Form 8-K; Period of report 2021-12-01; Description 7.01 Regulation FD Disclosure; Details 7.01.
- 2021-11-19: Form 8-K; Period of report 2021-11-19; Description 7.01 Regulation FD Disclosure; Details 7.01.
| Filed | Form | Period of report | Description | Details | Document |
|---|---|---|---|---|---|
| 2021-12-09 | 8-K | 2021-12-09 | 7.01 Regulation FD Disclosure | 7.01 On December 9, 2021, Zymeworks Inc. (“Zymeworks”) issued a press release announcing that its collaborator, BeiGene, Ltd., has dosed the first patient in South Korea in the HERIZON-GEA-01 trial. | d10637d8k.htm |
| 2021-12-09 | 8-K | 2021-12-08 | 7.01 Regulation FD Disclosure | 7.01 On December 8, 2021, Zymeworks Inc. (“Zymeworks”) issued a press release announcing new clinical data for the HER2-targeted bispecific antibody, zanidatamab, in heavily pretreated HER2-positive breast cancer. | d260676d8k.htm |
| 2021-12-01 | 8-K | 2021-12-01 | 7.01 Regulation FD Disclosure | 7.01 On December 1, 2021, Zymeworks Inc. (“Zymeworks”) issued a press release announcing that Janssen Biotech, Inc. (“Janssen”) dosed the first patient with JNJ-78306358, a bispecific antibody developed using Zymeworks’ Azymetric™ and EFECT™ therapeutic platforms. | d160486d8k.htm |
| 2021-11-19 | 8-K | 2021-11-19 | 7.01 Regulation FD Disclosure | 7.01 On November 19, 2021, Zymeworks Inc. (“Zymeworks”) issued a press release announcing the publication of an abstract highlighting new clinical data for zanidatamab, a HER2-targeted bispecific antibody. | d208558d8k.htm |
| 2021-11-09 | 8-K | 2021-11-09 | 7.01 Regulation FD Disclosure | 7.01 On November 9, 2021, Zymeworks Inc. (“Zymeworks”) issued a press release announcing, together with its partner BeiGene, the launch of HERIZON-GEA-01. | d217459d8k.htm |
| 2021-11-08 | 8-K | 2021-11-08 | 7.01 Regulation FD Disclosure | 7.01 • Stifel 2021 Virtual Healthcare Conference, November 16th - 17th. | d252309d8k.htm |
| 2021-11-03 | 8-K | 2021-11-03 | 2.02 Results of Operations and Financial Condition | 2.02 On November 3, 2021, Zymeworks Inc. (the “Company”) issued a press release announcing its financial results for the fiscal quarter ended September 30, 2021. | zyme-20211103.htm |
| 2021-10-26 | 8-K | 2021-10-26 | 7.01 Regulation FD Disclosure | 7.01 On October 26, 2021, Zymeworks Inc. (“Zymeworks”) issued a press release announcing that management will host a conference call and webcast to provide details related to the launch of its Phase 3 first-line gastroesophageal adenocarcinoma (GEA) pivotal study, HERIZON-GEA-01, and to discuss the commercial potential of zanidatamab in gastrointestinal cancers. | d247827d8k.htm |
| 2021-10-05 | 8-K | 2021-10-05 | 7.01 Regulation FD Disclosure | 7.01 On October 5, 2021, Zymeworks Inc. (“Zymeworks”) and ALX Oncology Inc. (“ALX”) issued a press release announcing the first patient has been dosed in an open-label, multi-center Phase 1b/2 clinical trial conducted by Zymeworks of zanidatamab (Zymeworks’ lead HER2-targeted bispecific antibody) in combination with evorpacept (ALX’s CD47 blocker). | d204577d8k.htm |
| 2021-10-01 | 8-K | 2021-10-01 | 1.01 Entry into a Material Definitive Agreement | 1.01 On October 1, 2021, Zymeworks Inc. (the “Company”) entered into an amendment (the “Amendment”) of its Open Market Sale AgreementSM, dated as of November 5, 2019, (as amended, the “Sales Agreement”) with Jefferies LLC (“Jefferies”) in connection with the Company’s filing of a new automatic shelf registration statement on Form S-3ASR (File No. 333-259970) (the “Registration Statement”), filed with the Securities and Exchange Commission (the “SEC”) on October 1, 2021. | d237389d8k.htm |
| 2021-09-16 | 8-K | 2021-09-16 | 7.01 Regulation FD Disclosure; 8.01 Other Events | 7.01 On September 16, 2021, Zymeworks Inc. (“Zymeworks”) issued a press release announcing that new clinical data for zanidatamab, a HER2-targeted bispecific antibody, demonstrate promising response rates and durability in first-line HER2-positive GEA. 8.01 On September 16, 2021, Zymeworks filed a material change report with the Canadian securities regulatory authorities on SEDAR regarding its announcement that (i) new clinical data for zanidatamab, a HER2-targeted bispecific antibody, demonstrate promising response rates and durability in first-line HER2-positive GEA, and (ii) these data were presented on September 16, 2021 by lead study investigator, Geoffrey Ku, M.D., Medical Oncologist at Memorial Sloan Kettering Cancer Center (MSK), at the ESMO Annual Congress. | d195420d8k.htm |
| 2021-09-13 | 8-K | 2021-09-12 | 7.01 Regulation FD Disclosure | 7.01 On September 12, 2021, Zymeworks Inc. (“Zymeworks”) issued a press release announcing the publication of an abstract highlighting new clinical data for zanidatamab, a HER2-targeted bispecific antibody, in first-line HER2-expressing GEA. | d202904d8k.htm |
| 2021-08-04 | 8-K | 2021-08-04 | 2.02 Results of Operations and Financial Condition | 2.02 On August 4, 2021, Zymeworks Inc. (the “Company”) issued a press release announcing its financial results for the fiscal quarter ended June 30, 2021. | zyme-20210804.htm |
| 2021-08-03 | 8-K | 2021-08-03 | 7.01 Regulation FD Disclosure | 7.01 On August 3, 2021, Zymeworks Inc. (“Zymeworks”) issued a press release announcing announced that Janssen Biotech, Inc. dosed the first patient with JNJ-78278343, a bispecific antibody developed using Zymeworks’ Azymetric™ and EFECT™ therapeutic platforms. | d364055d8k.htm |
| 2021-07-28 | 8-K | 2021-07-28 | 7.01 Regulation FD Disclosure | 7.01 On July 28, 2021, Zymeworks Inc. (“Zymeworks”) issued a press release announcing the first patient has been dosed with zanidatamab in combination with Tukysa® (tucatinib) and capecitabine in a new cohort of a Phase 1 trial for HER2-positive breast cancer patients with locally advanced (unresectable) and/or metastatic disease. | d155855d8k.htm |
| 2021-07-08 | 8-K | 2021-07-08 | 7.01 Regulation FD Disclosure | 7.01 On July 8, 2021, Zymeworks Inc. (“Zymeworks”) issued a press release announcing that Zymeworks will present at the upcoming Ladenburg Thalmann Healthcare Conference on July 14, 2021 at 4:00 p.m. | d197384d8k.htm |
| 2021-05-26 | 8-K | 2021-05-26 | 7.01 Regulation FD Disclosure | 7.01 On May 26, 2021, Zymeworks Inc. (“Zymeworks”) issued a press release announcing that Zymeworks will present at the upcoming Jefferies Virtual Healthcare Conference taking place June 1-4, 2021. | d162461d8k.htm |
| 2021-05-18 | 8-K/A | 2020-05-07 | 5.07 Submission of Matters to a Vote of Security Holders | 5.07 In the Company’s proxy statement with respect to the Company’s 2020 Annual Meeting, filed on March 23, 2020, the Company disclosed that its Board of Directors intended to hold say-on-pay votes in the future in accordance with the alternative that received the most shareholder support at the Company’s 2020 Annual Meeting. | d127748d8ka.htm |
| 2021-05-06 | 8-K | 2021-05-05 | 5.07 Submission of Matters to a Vote of Security Holders; 7.01 Regulation FD Disclosure | 5.07 On May 5, 2021, Zymeworks Inc. (the “Company”), held its 2021 annual meeting of shareholders (the “Annual Meeting”). 7.01 On May 6, 2021, the Company issued a press release announcing the voting results of its Annual Meeting, which was filed with the Canadian securities regulatory authorities in Canada on the System for Electronic Document Analysis and Retrieval (“SEDAR”) at www.sedar.com. | d623070d8k.htm |
| 2021-05-05 | 8-K | 2021-05-05 | 2.02 Results of Operations and Financial Condition | 2.02 On May 5, 2021, Zymeworks Inc. (the “Company”) issued a press release announcing its financial results for the fiscal quarter ended March 31, 2020. | zyme-20210505.htm |
| 2021-04-19 | 8-K | 2021-04-15 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; 7.01 Regulation FD Disclosure; 8.01 Other Events | 5.02 (b) On April 15, 2021, Diana Hausman, M.D., the Chief Medical Officer (“CMO”) of Zymeworks Inc. (“Zymeworks”), provided notice to Zymeworks of her resignation as CMO. 7.01 On April 19, 2021, Zymeworks issued a press release announcing that: (i) Dr. Hausman will be transitioning out of her role as Zymeworks’ CMO and assuming an executive advisory role until November 15, 2021; and (ii) Dr. Josephson, who currently oversees Zymeworks’ global clinical studies in his role as Senior Vice President, Clinical Research, will assume the role of interim CMO. 8.01 On April 19, 2021, the Company filed a material change report with Canadian securities regulators regarding: (i) Dr. Hausman’s transition out of her role as Zymeworks’ CMO and assumption of an executive advisory role, and (ii) Dr. Josephson’s assumption of the role of interim CMO. | d31123d8k.htm |
| 2021-04-13 | 8-K | 2021-04-13 | 7.01 Regulation FD Disclosure | 7.01 On April 13, 2021, Zymeworks Inc. (“Zymeworks”) issued a press release announcing that Zymeworks will present at the upcoming 2021 Bloom Burton Healthcare Investor Conference taking place April 20-21, 2021. | d149094d8k.htm |
| 2021-04-12 | 8-K | 2021-04-10 | 7.01 Regulation FD Disclosure | 7.01 On April 10, 2021, Zymeworks Inc. (“Zymeworks”) issued a press release announcing five presentations at the American Association for Cancer Research (AACR) Annual Meeting. | d124028d8k.htm |
| 2021-03-11 | 8-K | 2021-03-10 | 7.01 Regulation FD Disclosure | 7.01 On March 10, 2021, Zymeworks Inc. (“Zymeworks”) issued a press release announcing the acceptance of five abstracts for poster presentation at the upcoming American Association for Cancer Research (AACR) Annual Meeting 2021 taking place virtually from April 10 - 15, 2021. | d126078d8k.htm |
| 2021-02-24 | 8-K | 2021-02-24 | 2.02 Results of Operations and Financial Condition | 2.02 On February 24, 2021, Zymeworks Inc. (the “Company”) issued a press release announcing its financial results for the fiscal year ended December 31, 2020. | zyme-20210224.htm |
| 2021-02-10 | 8-K | 2021-02-10 | 7.01 Regulation FD Disclosure | 7.01 • Guggenheim Healthcare Talks Oncology Days, February 11-12, 2021. | d108998d8k.htm |
| 2021-02-10 | 8-K | 2021-02-09 | 7.01 Regulation FD Disclosure | 7.01 On February 9, 2021, Zymeworks Inc. (the “Company”) issued a press release announcing that James Priour, former Senior Vice President, Commercial, has been promoted to Chief Commercial Officer and named to the Company’s Executive Committee. | d127776d8k.htm |
| 2021-01-28 | 8-K | 2021-01-27 | 7.01 Regulation FD Disclosure | 7.01 On January 27, 2021, Zymeworks Inc. (“Zymeworks”) issued a press release announcing that: (i) the Company has begun enrolling patients into the expansion cohort portion of the ongoing Phase 1 clinical trial for ZW49, its novel HER2-targeted antibody-drug conjugate (ADC); and (ii) supporting data from the Phase 1 dose escalation portion were highlighted in a webcast and conference call on January 27, 2021, as summarized in the press release. | d42843d8k.htm |
| 2021-01-15 | 8-K | 2021-01-15 | 7.01 Regulation FD Disclosure | 7.01 On January 15, 2021, Zymeworks Inc. (“Zymeworks”) issued a press release announcing new and updated clinical data for the HER2-targeted bispecific antibody zanidatamab, in both HER2-expressing biliary tract cancer (BTC) and gastroesophageal adenocarcinoma (GEA). | d20680d8k.htm |
| 2021-01-11 | 8-K | 2021-01-11 | 7.01 Regulation FD Disclosure | 7.01 On January 11, 2021, Zymeworks Inc. (“Zymeworks”) issued a press release highlighting its key accomplishments in 2020 and updating its corporate priorities. | d109815d8k.htm |
| 2021-01-07 | 8-K | 2021-01-07 | 7.01 Regulation FD Disclosure | 7.01 On January 7, 2021, Zymeworks Inc. (“Zymeworks”) issued a press release announcing that: (i) management will present at the upcoming 39th Annual J.P. Morgan Healthcare Conference and (ii) Zymeworks will host two webcasts in January to discuss the zanidatamab clinical data presented at the American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO GI) and provide an update on ZW49’s clinical progress. | d69429d8k.htm |